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causing 30% of ulcer incidence and 30% of maximal efﬁcacy,
respectively. The plasma concentrations of ketoprofen after oral
administration of HCT 2037 (7.1 and 10.7 mg/kg) or equimolar
ketoprofen were assessed in separate male Sprague Dawley rats
using a HPLC MS/MS technique.
Results: HCT 2037 signiﬁcantly and dose-dependently decreased
paw edema formation. The highest dose tested (35.7 mg/kg) re-
duced edema formation by 59±6% vs. control (p<0.01) and the
ED30 was estimated to be 7.1 mg/kg, with a UD30 of 3.0 mg/kg.
The reference ketoprofen showed a 4-fold lower activity in inhibit-
ing edema formation (ED30>25 mg/kg), and caused marked GI
damage, with a UD30 of 1.3 mg/kg. By comparing ED30/UD30
ratios, HCT 2037 emerged as a more favourable compound than
ketoprofen (2.4 vs. >18.9, respectively). Pharmacokinetic analy-
sis following oral administration to rats of equimolar doses HCT
2037 or ketoprofen revealed that animals were exposed to similar
plasma concentrations of ketoprofen.
Conclusions: HCT 2037 showed a tendency towards a better ef-
ﬁcacy than ketoprofen in this model of inﬂammation, accompanied
by a three-fold improvement in gastric tolerability. HCT 2037 con-
ﬁrms that CINODs provide improved GI safety while maintaining
full anti-inﬂammatory effects in animals. If conﬁrmed in humans,
CINODs may represent a valuable therapeutic option for arthritic
pathologies.
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Purpose: Pathologic intervertebral disc (IVD) tissues contain
some macrophages and lymphocytes, as well as their proinﬂam-
matory cytokine products including TNFα, IL-1β, IL-8 and IFNγ.
TNFα is believed to be a key mediator of inﬂammation in multiple
IVD pathologies, with clinical interest in the delivery of TNF antag-
onists as therapeutic agents for attenuating symptoms of sciatica.
Soluble TNF receptors are potent TNF antagonists, capable of
high afﬁnity binding to TNFα thereby sequestering the cytokine
from cell receptors and downstream effects. Here, we characterize
the inﬂammatory phenotype of primary human IVD cells following
TNFα stimulation in vitro, and measure the potential antagonistic
activity of soluble TNF receptor II (sTNFRII).
Methods: Human IVD cells were isolated from to-be discarded
surgical tissues from patients undergoing surgery for degenerative
IVD pathology (n=11, age: 14 - 81yr). Human IVD cells were
seeded (50,000 cells/well, 48-well plates) in 300μl culture media
supplemented with 25 ng/ml rhTNFα (Abcam) and 10% FBS for
72 hrs; control cells received no TNFα. Four groups received a
dose of sTNFRII (12.5-100nM, Abcam) in addition to TNFα for
the 72h period. All supernatants were assayed for release of
nitric oxide (NO, n=11; Greiss reaction), and a subset of samples
were assayed for production of IL-6 and PGE2 (n=4; ELISA, R&D
Systems). All values were determined as differences from culture
media-only values at 72h, and normalized by control values for
cultures in the absence of TNFα to quantify the level of TNFα-
induction. Dose-dependent attenuation of TNFα-induction of NO,
PGE2 or IL-6 was then quantiﬁed by determining a 50% inhibitory
concentration (IC50). Statistical signiﬁcance was evaluated with
one-way ANOVA and a post-hoc Tukey’s HSD test.
Results: Pathologic IVD cells in the presence of TNFα exhibited
an inﬂammatory phenotype characterized by an average increased
production of NO (3-fold over control values of 11.0±2.73 μM),
PGE2 (67-fold over control of 188±245 pg/ml) and IL-6 (3-fold
over control of 703±421 pg/ml). These cellular responses to
TNFα are consistent with values reported previously for human
nucleus pulposus cells. Responses to TNFα were characterized by
signiﬁcant patient-to-patient variability, however, with a very large
range of values for NO, PGE2, and IL-6 quantiﬁed in supernatants.
Cells receiving a dose of sTNFRII exhibited some attenuation
of TNFα-induced responses, although the patient-variability was
signiﬁcant as for treatment with TNFα alone. sTNFRII attenuation
of TNFα effects followed a typical dose-dependent response in
IVD cells for measures of NO and PGE2 production, with IC50
values measured to be 29nM and 86nM, respectively.
Conclusions: These data conﬁrm previous reports of statistically
signiﬁcant increases in TNFα-induced release of NO, PGE2, and
IL-6 by human IVD cells and demonstrate that targeting TNFα
activity can attenuate the TNFα-induced upregulation of inﬂamma-
tory events of IVD cells These data point to a need for further
study of sTNFRII as a therapeutic candidate for treatment of IVD
pathologies, and support the current clinical interest in treating
sciatica with commercially available receptor analogues.
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Purpose: Knee osteoarthritis is a frequent cause of joint pain and
is estimated to be the most common cause of painful knee in
adults.It is very frequent in the Spanish population. According to
the EPISER study, performed by the Spanish Society of Rheuma-
tology, 29% of the Spanish population over age 60 showed symp-
tomatic knee osteoarthritis (KOA). The goals of management of
patients with knee osteoarthritis are to control pain, minimize dis-
ability, improve the quality of life, and educate the patient about
his or her role in the management team. The aim of this study
was to assess the pharmacological cost generated by a group of
patients diagnosed with knee osteoarthritis.
Methods: This is a transversal descriptive study performed in
2008. The study included 188 patients both male and female
over age 40, diagnosed with knee arthrosis (KOA) according to
ACR diagnostic criteria. Patients were collected from the OMI-AP
program database. This study analyzed the total number of drug
packs consumed per year per patient with KOA. The average cost
of each medication and the annual cost were then calculated. The
cost per patient per year was obtained as the total cost and total
number of patients ratio.
Results: Seventy-eight percent (78%) of patients included in the
study were female and 26% were male (3,5:1). The average age
was 69,22 years (DE ±9,29) and 56% of patients were older than
70 years and. Sixty-seven percent (67%) of the patients showed
bilateral KOA, 18% showed right knee involvement and 15% left
knee involvement.
NSAID were the most frequent prescribed drug to treat KOA
(36%) followed by SYSADOAs (17%), Paracetamol 1g. (14%),
topical treatments (13%), other painkillers such as metamizol,
opioids and tramadol (10%), and gastric protectors (10%). From
all NSAIDS, Diclofenac was the most frequent prescribed drug
(72 %) and Glucosamine Sulfate was the most frequent pre-
scribed SYSADOAs (65%). Chondrotin Sulfate and Diacerheine
represented 21% and 14% respectively.
From all prescribed drugs the highest spending was due to NSAIDs
administration (35%), followed by SYSADOAs (27%), painkillers
other than Paracetamol (18%), Paracetamol 1g. (8%) and topical
and IBP 6% each. Interestedly, although COXIB drugs repre-
